Published in Gene Therapy Weekly, December 22nd, 2005
The merger is subject to approval by the board of directors of each company and their respective shareholders. The Diamyd Medical board of directors plans to request shareholder approval for the merger at the annual general shareholders meeting on December 12, 2005.
Diamyd Medical has valued Nurel at US$1.5 million....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.